CA3177652A1 - Methods of treating pulmonary fibrosis - Google Patents

Methods of treating pulmonary fibrosis Download PDF

Info

Publication number
CA3177652A1
CA3177652A1 CA3177652A CA3177652A CA3177652A1 CA 3177652 A1 CA3177652 A1 CA 3177652A1 CA 3177652 A CA3177652 A CA 3177652A CA 3177652 A CA3177652 A CA 3177652A CA 3177652 A1 CA3177652 A1 CA 3177652A1
Authority
CA
Canada
Prior art keywords
pulmonary fibrosis
formula
compound
treatment
lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3177652A
Other languages
English (en)
French (fr)
Inventor
Chris Burns
John Lambert
Mark Graeme DEVLIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amplia Therapeutics Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020901743A external-priority patent/AU2020901743A0/en
Application filed by Individual filed Critical Individual
Publication of CA3177652A1 publication Critical patent/CA3177652A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3177652A 2020-05-28 2021-05-17 Methods of treating pulmonary fibrosis Pending CA3177652A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020901743 2020-05-28
AU2020901743A AU2020901743A0 (en) 2020-05-28 Methods of treating pulmonary fibrosis
PCT/AU2021/050457 WO2021237273A1 (en) 2020-05-28 2021-05-17 Methods of treating pulmonary fibrosis

Publications (1)

Publication Number Publication Date
CA3177652A1 true CA3177652A1 (en) 2021-12-02

Family

ID=78745664

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3177652A Pending CA3177652A1 (en) 2020-05-28 2021-05-17 Methods of treating pulmonary fibrosis

Country Status (9)

Country Link
US (1) US20230190746A1 (https=)
EP (1) EP4157278A4 (https=)
JP (1) JP7745571B2 (https=)
KR (1) KR20230017843A (https=)
CN (1) CN115867281A (https=)
AU (1) AU2021279205B2 (https=)
CA (1) CA3177652A1 (https=)
NZ (1) NZ793855A (https=)
WO (1) WO2021237273A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3001119T3 (es) 2019-03-28 2025-03-04 Amplia Therapeutics Ltd Una sal y forma cristalina de un inhibidor de FAK
WO2023139154A1 (en) * 2022-01-19 2023-07-27 Nordic Bioscience A/S A method for detecting covid-19 in a patient

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9174946B2 (en) * 2011-02-17 2015-11-03 Cancer Therapeutics Crc Pty Ltd Selective FAK inhibitors
WO2014027199A1 (en) * 2012-08-14 2014-02-20 Cancer Therapeutics Crc Pty Ltd Fak and flt3 inhibitors
ES3001119T3 (es) * 2019-03-28 2025-03-04 Amplia Therapeutics Ltd Una sal y forma cristalina de un inhibidor de FAK

Also Published As

Publication number Publication date
JP7745571B2 (ja) 2025-09-29
US20230190746A1 (en) 2023-06-22
WO2021237273A1 (en) 2021-12-02
KR20230017843A (ko) 2023-02-06
NZ793855A (en) 2026-02-27
CN115867281A (zh) 2023-03-28
EP4157278A4 (en) 2024-07-03
EP4157278A1 (en) 2023-04-05
AU2021279205A1 (en) 2022-12-08
JP2023527358A (ja) 2023-06-28
AU2021279205B2 (en) 2025-12-04

Similar Documents

Publication Publication Date Title
US20230146291A1 (en) Treatment of Respiratory Diseases
US20220152055A1 (en) Methods and compositions for treating various disorders
ES2666098T3 (es) Combinación de fármacos
EP3551187B1 (en) Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol
KR20090024281A (ko) 다발성 경화증 치료용 ｓ１ｐ 수용체 조절제
US12427142B2 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl[oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid
EP4322941A1 (en) Combination comprising ribociclib and amcenestrant
AU2021279205B2 (en) Methods of treating pulmonary fibrosis
BRPI0716214A2 (pt) Composições farmacêuticas para o tratamento de infecções fúngicas.
JP6929860B2 (ja) 手湿疹の治療
US9446029B2 (en) Use of NK-1 receptor antagonists in management of visceral pain
US11571410B2 (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
JP7399502B2 (ja) びらん性変形性手関節症の治療のためのモンテルカスト
US20120083510A1 (en) Perfluorocarbons for use in treating pruritus
JP6051315B2 (ja) 乾癬を処置するためのピドチモドの使用
JP2022540198A (ja) 組合せ
EP4175639B1 (en) Masitinib for the treatment of castrate-resistant prostate cancer
RU2809024C2 (ru) Монтелукаст для лечения эрозивного остеоартрита кистей рук
KR20190087570A (ko) 가려움증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
CN121443299A (zh) 用于治疗脏器纤维化相关疾病的药物组合物和方法
JP6414727B2 (ja) 関節疾患の治療予防剤
JP2019518045A (ja) チモロール及び抗炎症剤を含む組成物
CN119522109A (zh) 用于钙调磷酸酶抑制剂的间歇性给药的组合物
HK40015213A (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250217

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250217

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250217

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250224

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250224

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250224

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250224

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250506

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250506

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250506

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260113

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260407

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260413

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260413

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260413